Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single ascending dose (SAD) portion of the study with the doses from 300 mg to 2,000 mg in 32 healthy volunteers and…
Modified mRNA sequence of the Spike protein prevents cleavage of the expressed protein, which may potentially result in a cleaner safety profile.Pre-clinical data supporting the investigational new drug application has been published in…
Topline safety and pharmacokinetic (PK) data from the Phase I single ascending dose (SAD)/multiple ascending dose (MAD) study of STI-1558 in 58 healthy volunteers in Australia are now available. The SAD portion of the study evaluated doses…
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for long-term safety and efficacy outcomes…
SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento…
Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved significant improvements in disease activity…
SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following:More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data…
STI-1558, an oral SARS-CoV-2 main protease (Mpro) inhibitor, which can block viral replication, is specifically designed as a standalone treatment of COVID-19 without ritonavir as a booster.Single ascending dose (SAD) portion of the Phase…
PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical…